The Payer's Dilemma on Syam Adusumilli

Is MA Still Worth It?

Sun, 15 Mar 2026 00:00:00 +0000

Every MA plan board, every health insurer CFO, and every healthcare investor is running the same calculation in 2026. Medicare Advantage grew to over 55% of Medicare enrollment on the strength of zero-premium plans, rich supplemental benefits, aggressive broker distribution, and a coding-driven revenue model that generated returns exceeding those of any other insurance line of business. The 0.09% advance notice is the trigger for the current reassessment, but the question is structural. Can private insurers generate sustainable returns in MA when CMS is simultaneously compressing rates, tightening risk adjustment, excluding chart reviews, and signaling encounter-based RA?

Summary: Is MA Still Worth It?

Sun, 15 Mar 2026 00:00:00 +0000

Every MA plan board, health insurer CFO, and healthcare investor is running the same calculation in 2026. Medicare Advantage grew to over 55% of Medicare enrollment on zero-premium plans, rich supplemental benefits, aggressive broker distribution, and a coding-driven revenue model that generated returns exceeding every other insurance line of business. The 0.09% advance notice is the trigger for the current reassessment, but the question is structural: can private insurers generate sustainable returns when CMS is simultaneously compressing rates, tightening risk adjustment, excluding chart reviews, and signaling encounter-based RA? The answer depends entirely on what operating model a given plan has built.

Benefit Design 2026-2027

Sun, 15 Mar 2026 00:00:00 +0000

The rate environment dictates the benefit environment. What CMS proposed in January 2026 determines what plans can afford to offer in January 2027. The CY 2027 benefit packages that plans submit in their June bids will be the first designed entirely within the post-chart-review-exclusion, post-V28, 0.09% rate world. This article maps the supplemental benefit contraction already underway in 2026, the Part D changes reshaping drug coverage, and the gap between what beneficiaries believe their plans cover and what the economics actually support.

Summary: Benefit Design 2026-2027

Sun, 15 Mar 2026 00:00:00 +0000

The rate environment dictates the benefit environment. What CMS proposed in January 2026 determines what plans can afford to offer in January 2027. The CY 2027 benefit packages that plans submit in their June bids will be the first designed entirely within the post-chart-review-exclusion, post-V28, 0.09% rate world. The contraction is already visible in 2026 data and will accelerate for 2027.

KFF’s analysis of 2026 plan benefit packages found that while core supplemental benefits remain nearly universal, with 99% of plans offering vision, 98% dental, and 98% hearing, the share offering non-core supplementals declined meaningfully. HealthScape’s survey of over 35 MA plan leaders found that nearly 70% expected 2027 benefits to be less rich than 2026. Not one leader expected richer benefits. The degradation for 2027 is sharpest in the non-core supplemental category. Dental benefits are narrowing from major restorative work first, with annual caps declining from $2,000 toward $1,000 across successive plan years. Vision eyewear allowances are declining from $200 toward $100 for 2027, making the benefit functionally symbolic for beneficiaries needing progressive lenses. Hearing aid coverage is increasing cost-sharing and reducing covered device ranges. OTC allowances dropped from 73% of plans in 2025 to 66% in 2026, with quarterly amounts declining from $100 or more to $25 to $50 at many plans. Transportation benefits are reducing covered trip counts, tightening eligibility to medical appointments only, and imposing advance scheduling requirements. Meal delivery benefits declined from 61% of plans in 2025 to 57% in 2026, with stricter chronic condition eligibility criteria. SSBCI benefits, which had expanded under the VBID demonstration that ended December 2024, now survive only to the extent the rebate math supports them.

The Broker Compensation Wars

Sun, 15 Mar 2026 00:00:00 +0000

The broker and agent channel is where Medicare policy meets the kitchen table. Compensation rules, enforcement actions, and regulatory posture determine who sells what to whom and on what terms. In 2025 and 2026, three forces collided: CMS tightened broker compensation and marketing rules under the Biden administration, DOJ brought a blockbuster False Claims Act action against three major insurers and three major brokerages, and a federal court struck down parts of the compensation regulatory framework, all while the new administration signaled a deregulation pivot through the CY 2027 proposed rule. The result is a broker ecosystem operating under simultaneous deregulatory signals from CMS, active enforcement from DOJ, and legal uncertainty from the courts.

Summary: The Broker Compensation Wars

Sun, 15 Mar 2026 00:00:00 +0000

Three forces hit the Medicare broker ecosystem simultaneously in 2025 and 2026: CMS tightened broker compensation and marketing rules under the Biden administration, DOJ filed a blockbuster False Claims Act complaint against three major insurers and three major brokerages, and a federal court struck down parts of the compensation regulatory framework, all while the new CMS administration signaled a deregulatory pivot through the CY 2027 proposed rule. The result is a broker channel operating under simultaneous deregulatory signals from CMS, active enforcement from DOJ, and legal uncertainty from the courts.

The TPMO Ecosystem

Sun, 15 Mar 2026 00:00:00 +0000

Between the beneficiary and the plan sits an industry most seniors have never heard of. Third Party Marketing Organizations, Field Marketing Organizations, and national marketing organizations control the distribution pipeline for a significant share of Medicare Advantage enrollment. They generate leads, route calls, assign agents, and facilitate enrollments at a scale that makes them structural participants in the Medicare market rather than peripheral service providers. The DOJ’s May 2025 complaint against eHealth, GoHealth, and SelectQuote (MCR-04.03) exposed the financial arrangements underlying this pipeline. This article examines the architecture itself: who the entities are, how the money flows, why the structure incentivizes volume over quality, and what the beneficiary actually experiences on the receiving end.

Summary: The TPMO Ecosystem

Sun, 15 Mar 2026 00:00:00 +0000

Between the beneficiary and the plan sits an industry most seniors have never heard of. Third Party Marketing Organizations, Field Marketing Organizations, and national marketing organizations control the distribution pipeline for a significant share of Medicare Advantage enrollment. They generate leads, route calls, assign agents, and facilitate enrollments at a scale that makes them structural participants in the Medicare market. The DOJ’s May 2025 complaint against eHealth, GoHealth, and SelectQuote exposed the financial arrangements underlying this pipeline. The architecture itself, who the entities are, how money flows, and why the structure incentivizes volume over quality, determines what the beneficiary actually experiences.

The Independent Agent's Dilemma

Sun, 15 Mar 2026 00:00:00 +0000

The independent Medicare agent occupies an impossible position in 2026. Compensated by plans, expected to serve beneficiaries, operating without fiduciary standards, and now selling a product whose value proposition is visibly deteriorating. The previous two articles in this trilogy examined the regulatory and enforcement landscape (MCR-04.03) and the TPMO distribution architecture (MCR-04.04). This article turns to the individual agent: the person across the kitchen table from the beneficiary, explaining coverage options while navigating a compensation structure that may not reward the right recommendation.

Summary: The Independent Agent's Dilemma

Sun, 15 Mar 2026 00:00:00 +0000

The independent Medicare agent occupies an impossible structural position in 2026. Compensated by plans, expected to serve beneficiaries, operating without fiduciary standards, and now selling a product whose value proposition is visibly deteriorating. The structural problem is not that agents are bad actors. It is that the incentive architecture within which they operate does not reliably produce beneficiary-aligned outcomes, and the benefit environment has shifted in ways that make the incentive conflicts more consequential than they were when MA plans were flush with supplemental benefit funding.

Regional Plans vs. National Giants

Sun, 15 Mar 2026 00:00:00 +0000

The 0.09% rate environment is a stress test, and different plan types fail at different pressure levels. National carriers, regional nonprofits, provider-sponsored plans, and PACE organizations each face the same CMS advance notice from a different structural position. Their chart review dependence, Star Rating profiles, administrative cost structures, provider network relationships, and access to delivery system revenue vary in ways that produce fundamentally different survival calculus under rate compression. This article maps who is most exposed, who has the strongest defensive position, and why the competitive landscape that emerges from the CY 2027 rate cycle will look substantially different from the one that entered it.

Summary: Regional Plans vs. National Giants

Sun, 15 Mar 2026 00:00:00 +0000

The 0.09% rate environment is a stress test, and different plan types fail at different pressure levels. National carriers, regional nonprofits, provider-sponsored plans, and PACE organizations each face the same CMS advance notice from structurally different positions. Their chart review dependence, Star Rating profiles, administrative cost structures, provider network relationships, and access to delivery system revenue vary in ways that produce fundamentally different survival calculus under rate compression.

National carriers hold approximately 60% of national MA enrollment. Their scale advantages are real: administrative costs per member decline as enrollment grows, PBM integration provides pharmacy benefit synergies, and data analytics infrastructure enables bid optimization that smaller plans cannot replicate. But scale does not fix a money-losing county. Each county operates as a separate economic unit with its own benchmark, utilization profile, and competitive dynamics. When rate compression hits the entire portfolio simultaneously, scale amplifies aggregate loss rather than mitigating it. National carriers manage through a combination of benefit reduction, premium increase, network tightening, and selective exit. UnitedHealth’s 2026 contraction of 1.3 to 1.4 million members was a portfolio optimization exercise: exit counties where margin was worst, concentrate resources in profitable geographies. The chart review exclusion creates additional differentiation among national carriers because chart review intensity is not uniform. Mizuho’s identification of CVS/Aetna as particularly exposed to the $7.2 billion exclusion illustrates that the reform functions as a within-tier sorting mechanism penalizing coding-dependent business models regardless of carrier size.

Star Ratings in Transition

Sun, 15 Mar 2026 00:00:00 +0000

Star Ratings are not just a quality metric. They are a financial instrument whose dollar value increases as the rate environment compresses. The 5% benchmark bonus for plans rated 4 stars or above can mean the difference between market viability and county exit in a 0.09% rate world. A plan that holds 4 stars has a revenue floor its competitors below that threshold do not. A plan that drops from 4 to 3.5 stars loses a revenue stream that no operational efficiency can replace. The CY 2027 proposed rule restructures the Star Ratings measure set, reverses the Health Equity Index reward, and solicits industry input on whether the entire Quality Bonus Payment structure should be reformed. Each of these changes alters the strategic calculus for quality investment at a moment when the margin available for that investment is at its narrowest.

Summary: Star Ratings in Transition

Sun, 15 Mar 2026 00:00:00 +0000

Star Ratings are not just a quality metric. They are a financial instrument whose dollar value increases as the rate environment compresses. The 5% benchmark bonus for plans rated 4 stars or above can mean the difference between market viability and county exit in a 0.09% rate world. In a county with a $1,100 monthly benchmark, that bonus produces $55 PMPM in additional benchmark-derived revenue, which for a 100,000-member plan is worth $66 million annually. The 3.5-to-4-star threshold is binary: a plan at 3.5 stars receives zero additional benchmark revenue; a plan at 4 stars receives 5%. Humana’s 2025 experience, where the share of members in 4-star or above plans collapsed from 94% to 25% through narrow cut-point misses on individual measures, demonstrated at scale how quickly the revenue floor disappears and how hard it is to recover.

MA Market Consolidation

Sun, 15 Mar 2026 00:00:00 +0000

Rate compression produces consolidation. The relationship is mechanical: when payment rates decline or flatten, plans operating at the margin exit, plans seeking scale acquire, and new entrants identify gaps left by departing incumbents. The last time Medicare Advantage faced significant payment pressure, during the ACA-era benchmark reductions from 2010 through 2015, hundreds of plan contracts exited, enrollment temporarily declined for the first time in the program’s history, and the market restructured around fewer, larger entities that emerged from the contraction with stronger competitive positions. The CY 2027 rate environment carries the same structural dynamics at a fundamentally different scale. MA now covers 55% of Medicare beneficiaries, more than double the penetration during the ACA consolidation. The risk adjustment tightening is not a one-time benchmark cut that plans can absorb and grow past; it is a structural recalibration toward encounter-based RA that changes how plans generate revenue permanently. And the payvider model, which barely existed during ACA consolidation, now represents a viable alternative organizational form that may absorb share from departing standalone insurers.

Summary: MA Market Consolidation

Sun, 15 Mar 2026 00:00:00 +0000

Rate compression produces consolidation. The relationship is mechanical: when payment rates flatten, plans operating at the margin exit, plans seeking scale acquire, and new entrants identify gaps left by departing incumbents. The ACA-era benchmark reductions from 2010 through 2015 produced the last significant consolidation cycle, reducing MA plan contracts from over 3,100 to approximately 2,400 and concentrating enrollment in fewer, larger carriers. The CY 2027 rate environment carries the same structural dynamics at a fundamentally different scale: MA now covers 55% of Medicare beneficiaries, the risk adjustment tightening is structural and permanent rather than cyclical, and the payvider model now represents a viable organizational alternative that did not exist during the ACA consolidation.

Part D in 2026-2027

Sun, 15 Mar 2026 00:00:00 +0000

Part D is being reshaped simultaneously by four forces that have never operated in concert before. The IRA’s drug price negotiation program placed the first ten Maximum Fair Prices into effect on January 1, 2026, with fifteen more drugs selected for 2027. The GUARD model imposes mandatory rebates on Part D drugs whose prices exceed inflation-adjusted thresholds. BALANCE introduces GLP-1 coverage for weight management through a Part D bridge starting July 2026 and a full CMMI model in January 2027. And the $2,000 annual out-of-pocket cap, fully operational in 2026, restructures the benefit design in which all of these changes land. Each of these forces alters the formulary, cost-sharing, and plan liability calculus that Part D plan teams use to build benefit packages and submit bids. Together they produce the most complex Part D operating environment since the benefit’s creation in 2006.

Summary: Part D in 2026-2027

Sun, 15 Mar 2026 00:00:00 +0000

Part D is being reshaped simultaneously by four forces that have never operated in concert: the IRA’s drug price negotiation program, with the first ten Maximum Fair Prices in effect and fifteen more drugs selected for 2027; the GUARD model imposing mandatory rebates on drugs whose prices exceed inflation-adjusted thresholds; BALANCE introducing GLP-1 weight management coverage through a Part D bridge starting July 2026 and a full CMMI model in January 2027; and the $2,000 annual out-of-pocket cap, fully operational in 2026. Together they produce the most complex Part D operating environment since the benefit’s creation in 2006.

Medicare Fraud, Waste, and Abuse

Sun, 15 Mar 2026 00:00:00 +0000

Medicare loses more to improper payments than most countries spend on their entire health systems. CMS’s FY 2025 improper payment estimates totaled approximately $57 billion across Medicare FFS ($28.83 billion at a 6.55% error rate), Medicare Part C ($23.67 billion at 6.09%), and Medicare Part D ($4.23 billion at 4.00%). These figures are not fraud estimates. They measure payments that did not meet program requirements, encompassing overpayments, underpayments, and payments where insufficient documentation prevented a determination of whether the payment was proper. The actual fraud figure is unmeasurable with precision because fraud, by definition, involves concealment. But the improper payment estimates establish a floor: at least $57 billion annually flows through Medicare in ways the program’s own rules do not authorize, and the enforcement apparatus recovers only a fraction of it.

Summary: Medicare Fraud, Waste, and Abuse

Sun, 15 Mar 2026 00:00:00 +0000

Medicare loses more to improper payments than most countries spend on their entire health systems. CMS’s FY 2025 improper payment estimates totaled approximately $57 billion: Medicare FFS at $28.83 billion (6.55% error rate), Medicare Part C at $23.67 billion (6.09%), and Medicare Part D at $4.23 billion (4.00%). These are not fraud estimates. They measure payments that did not meet program requirements. The actual fraud figure is unmeasurable with precision because fraud involves concealment. But the improper payment estimates establish a floor: at least $57 billion annually flows through Medicare in ways the program’s own rules do not authorize, and the enforcement apparatus recovers only a fraction of it.

Private Equity in Medicare Delivery

Sun, 15 Mar 2026 00:00:00 +0000

Private equity has become one of the largest ownership categories in Medicare-dependent healthcare delivery. The investment thesis is straightforward: Medicare payment streams are predictable, utilization is growing as the population ages, and a fragmented delivery landscape creates roll-up opportunities where scale produces operating leverage. The capital flows in. Physician practices, home health agencies, hospices, skilled nursing facilities, behavioral health providers, urgent care chains, and dental groups are acquired, consolidated, and optimized for financial return within a three-to-seven-year hold period. The question this article examines is whether the PE ownership model, characterized by leveraged acquisition, cost reduction as a primary margin driver, rapid growth through consolidation, and exit through sale or IPO, is compatible with the quality, continuity, and accessibility that Medicare beneficiaries need from the providers who care for them.

Summary: Private Equity in Medicare Delivery

Sun, 15 Mar 2026 00:00:00 +0000

Private equity has become one of the largest ownership categories in Medicare-dependent healthcare delivery. The investment thesis is straightforward: Medicare payment streams are predictable, utilization is growing as the population ages, and a fragmented delivery landscape creates roll-up opportunities where scale produces operating leverage. The question is whether the PE ownership model, characterized by leveraged acquisition, cost reduction as the primary margin driver, and exit through sale or IPO within three to seven years, is compatible with the quality, continuity, and accessibility that Medicare beneficiaries need from the providers who care for them. The peer-reviewed evidence base has grown substantially, and it points in a consistent direction.

The IRA Drug Negotiation Process

Sun, 15 Mar 2026 00:00:00 +0000

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program is the most structurally significant drug pricing reform since Part D was created in 2003. For the first time, Medicare can negotiate prices directly with manufacturers for high-expenditure, single-source drugs, a power the program was explicitly prohibited from exercising under the Medicare Modernization Act’s non-interference clause since Part D’s inception. The first ten negotiated Maximum Fair Prices took effect January 1, 2026. Fifteen additional drugs are selected for 2027 prices, including the first Part B drugs. Manufacturers have challenged the program’s constitutionality in federal courts across the country and lost on the merits in every case decided so far, ten district court decisions and six circuit court decisions, though AstraZeneca has petitioned the Supreme Court for review.

Summary: The IRA Drug Negotiation Process

Sun, 15 Mar 2026 00:00:00 +0000

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program is the most structurally significant drug pricing reform since Part D was created in 2003. For the first time, Medicare can negotiate prices directly with manufacturers for high-expenditure, single-source drugs, a power the program was explicitly prohibited from exercising under the non-interference clause in the Medicare Modernization Act. The first ten negotiated Maximum Fair Prices took effect January 1, 2026. Fifteen additional drugs are selected for 2027, including the first Part B drugs. Manufacturers have challenged the program in federal courts and lost on the merits in every case decided so far, ten district court decisions and six circuit court decisions, though AstraZeneca has petitioned the Supreme Court for review.